| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4030970 | Ophthalmology | 2006 | 16 Pages |
Abstract
The 2-year safety profile of pegaptanib sodium is favorable in patients with exudative AMD.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Donald J. D'Amico, VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group,